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The TEM-107 extended-spectrum -lactamase detected in a Klebsiella pneumoniae clinical isolate had a
Gly238Ser substitution compared to the TEM-43 -lactamase. The MIC of ceftazidime was higher (64 g/ml)
than that of cefotaxime (2 g/ml) for the isolate. Clavulanic acid reduced the MIC of ceftazidime 64-fold.
Numerous TEM-type extended-spectrum -lactamases (ESBLs)
have been reported since the first detection of TEM-12 in 1982 (7).
It was reported that TEM-52 is a predominant TEM-type
ESBL in South Korea (6). TEM-52-producing isolates had the
unusual feature of decreased susceptibility to moxalactam, and
the enzyme hydrolyzed cefotaxime more efficiently than it hy-
drolyzed ceftazidime (6, 8). TEM-107 (GenBank accession no.
AY101764) is a novel ESBL found in a Klebsiella pneumoniae
isolate (YMC 99/12/94) that colonized the throat of a 17-year-
old hospitalized Korean girl with diarrhea. TEM-107 has an
additional Gly238Ser substitution (Table 1) compared to
TEM-43 (13). Although TEM-107 has only a single additional
amino acid substitution (Arg164His) compared to TEM-52,
the isolate showed a higher resistance to ceftazidime than to
cefotaxime (6, 8). Therefore, we were interested in determin-
ing the biochemical characteristics of TEM-107.
The antimicrobial agents used in this study were ampicillin,
cephalothin, and colistin (Sigma Chemical, St. Louis, MO),
piperacillin, tazobactam, and tigecycline (Wyeth, Pearl River,
NY), cefotetan (Kukje, Sungnam, South Korea), cefotaxime
(Handok, Seoul, South Korea), cefuroxime, ceftazidime, and
clavulanic acid (GlaxoSmithKline, Greenford, United King-
dom), cefepime and aztreonam (Bristol-Myers Squibb, Plains-
boro, NJ), moxalactam (Eli Lilly, Indianapolis, IN), cefoxitin,
ertapenem, and imipenem (Merck Sharp & Dohme, Rahway,
NJ), and meropenem (Sumitomo, Tokyo, Japan). The MICs of
antimicrobial agents were determined by the CLSI agar dilu-
tion method (2). ESBL production was tested by the double
disk synergy test (12). Escherichia coli ATCC 25922 and K.
pneumoniae ATCC 700603 were used as control strains.
Resistance to -lactams was transferred to E. coli J53 recip-
ient by agar mating and using Mueller-Hinton agar containing
ceftazidime (2 g/ml) and sodium azide (100 g/ml). The K.
pneumoniae isolate with TEM-107 and the transconjugant ex-
hibited the typical ESBL phenotype (Table 2) and gave posi-
tive results by the double-disk synergy test. The MICs of cef-
tazidime and cefotaxime for the clinical isolate were 64 g/ml
and 2 g/ml, respectively, and the MICs decreased by at least
8-fold when clavulanic acid or tazobactam was also included. It
was reported that the MIC of cefotaxime was higher than that
of ceftazidime for K. pneumoniae isolates with TEM-52 (6).
Two amino acid substitutions in TEM variants, Glu104Lys and
Gly238Ser, were associated with high-level resistance to cefo-
taxime (5). Both TEM-107 and TEM-43 have Arg164His sub-
stitutions, a change frequently observed in TEM-type ESBLs
(1, 3, 13), which confer a higher level resistance to ceftazidime
than to cefotaxime (5). The MIC of moxalactam was 1 g/ml
for the TEM-107-producing isolate.
Preparation of recombinant plasmid and transformation of
competent E. coli were performed as described previously (10).
Briefly, the blaTEM-107 open reading frame was amplified by
PCR using primers ET9-F (F stands for forward) (5-GGG
GCA TAT GAG TAT TCA ACA TTT TCG-3) and ET9-R
(R stands for reverse) (5-CCG GAT CCT TAC CAA TGC
TTA ATC AGT-3); each of these two primers was designed to
include restriction sites NdeI and BamHI, respectively, allow-
ing it to be cloned in the pET9a vector, and it was subsequently
transformed in E. coli XL-1 Blue or BL21(DE3) laboratory
strains.
TEM-107 -lactamase was produced and purified using the
following procedure. E. coli BL21(DE3) (pET9a/blaTEM-107)
was grown in 6 liters of ZYP-5052 autoinducing rich medium
(11) supplemented with 100 g/ml kanamycin, 50 g/ml am-
picillin, and 2 mg/ml oxgall (Difco Laboratories, Detroit, MI)
at 35°C for 24 h. With the addition of oxgall to the medium,
most -lactamase activity was found in the culture supernatant
(4). The proteins were precipitated by the addition of ammo-
nium sulfate (70% saturation) to the supernatant, and the
solution was mixed for 45 min at 4°C. Precipitated proteins
were separated by centrifugation and resuspended in 50 mM
phosphate buffer (pH 7.0). The sample was desalted using a
HiPrep 26/10 column and loaded on a Hitrap ANX FF column
using 50 mM Tris buffer (pH 7.5). -Lactamase-containing
fractions, eluted using a linear NaCl gradient, were pooled and
loaded onto a Resource Q column (bed volume, 1 ml) using 20
mM Tris buffer (pH 7.5) for further purification. The purity of
the preparation was estimated to be higher than 95% by so-
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dium dodecyl sulfate-polyacrylamide gel electrophoresis. Iso-
electric focusing showed that the protein had an approximate
pI of 6.0 (data not shown).
For enzyme assays, purified TEM-107 -lactamase was di-
luted in 50 mM phosphate buffer (pH 7.0) containing 20 g/ml
of bovine serum albumin (BSA). Kinetic parameters were de-
termined as described previously with some modifications (10).
Briefly, the initial rates of hydrolysis for -lactam substrates
were measured at 30°C using a spectrophotometer (UV-2401;
Shimadzu Corp., Tokyo, Japan). Ten microliters of enzyme
was added to 600 l of antibiotic solution in 50 mM phosphate
buffer (pH 7.0). The steady-state kinetic parameters were com-
puted using the Hanes-Wolff linearization of the Michaelis-
Menten equation. For poor substrates with Km values lower
than 10, Km was measured as the competitive inhibition con-
stant (Ki) determined in competition experiments using 20 M
nitrocefin as the reporter substrate.
TEM-107 efficiently hydrolyzed several -lactams (Table 3).
In terms of turnover rates, TEM-107 was clearly more active
on ceftazidime (kcat, 16 s
1) than on cefotaxime, cefepime, or
aztreonam (kcat, 3 s
1). Hydrolysis of moxalactam and ce-
foxitin could not be observed with enzyme concentrations up to
585 nM in the reaction mixture, although these two com-
pounds were able to interact with TEM-107, as revealed by
competition assays (Ki, 26 and 48 M, respectively). The kcat
value of TEM-107 for aztreonam was 2 s1, whereas the cat-
alytic activity of TEM-52 was very low (6). Improved catalytic
efficiency was reported against ceftazidime and aztreonam by
an Arg164His change in TEM-109 (9), which is also present in
TEM-107.
The kcat/Km values of TEM-107 were slightly higher for
cefotaxime, ceftazidime, cefepime, and aztreonam (1.2  105
to 1.8  105 M1  s1) than for cephalothin and cefuroxime
(6.7 104 to 7.9 104 M1  s1) (Table 3). The kcat/Km value
of TEM-107 for ceftazidime (1.8  105 M1  s1) was slightly
higher than that for cefotaxime (1.2  105 M1  s1), which
was similar to that of TEM-43 (13).
TABLE 1. Amino acid substitutions in TEM-107 compared to the
amino acids in TEM-1, TEM-43, and TEM-52
-Lactamase
Residue at amino acid position:
104 164 182 238
TEM-1 Glu Arg Met Gly
TEM-43 Lys His Thr Gly
TEM-52 Lys Arg Thr Ser
TEM-107 Lys His Thr Ser
TABLE 2. MICs of -lactams and other antimicrobial agents for an isolate, a transconjugant, and a cloned strain with blaTEM-107
Antimicrobial agenta
MIC (g/ml)
K. pneumoniae
(TEM-107)
E. coli transconjugant
(TEM-107)
E. coli J53
recipient
E. coli XL1-Blue
(TEM-107) E. coli XL1-Blue
K. pneumoniae
(TEM-52)b
Ampicillin 1,024 256 4 32 4 256c
Ampicillin-CLA 4 4 2 4 2 6c
Piperacillin 128 64 1 32 1 NT
Piperacillin-TZB 4 2 1 0.5 0.5 NT
Cephalothin 32 32 16 16 8 256
Cefuroxime 8 8 8 8 4 NT
Cefotaxime 2 1 0.12 0.12 0.06 256
Cefotaxime-CLA 0.12 0.12 0.12 0.06 0.06 NT
Ceftazidime 64 32 0.25 4 0.25 192
Ceftazidime-CLA 1 1 0.25 0.25 0.12 NT
Cefepime 2 1 0.12 0.12 0.06 NT
Cefepime-CLA 0.25 0.25 0.12 0.12 0.06 NT
Azteonam 8 8 0.25 0.5 0.12 16
Moxalactam 1 1 1 0.5 0.5 4
Cefoxitin 8 8 8 8 8 NT
Cefotetan 0.25 0.5 0.5 0.5 0.25 8
Ertapenem 0.03 0.03 0.008 NT NT NT
Imipenem 0.12 0.25 0.25 0.25 0.25 NT
Meropenem 0.06 0.06 0.06 0.06 0.06 NT
Tigecycline 0.5 0.12 0.12 NT NT NT
Colistin 0.5 0.5 0.5 NT NT NT
a Abbreviations: CLA, clavulanic acid (1/2 concentration of antibiotics); TZB, tazobactam (4 g/ml constant concentration); NT, not tested.
b Based on data from reference 7.
c These two values are the MICs of amoxicillin and amoxicillin-CLA instead of ampicillin and ampicillin-CLA, respectively.
TABLE 3. Kinetic properties of the purified TEM-107 -lactamase
with various -lactam compoundsa
Substrate kcat (s1) Km (M) kcat/Km (M1  s1)
Nitrocefin 72 5 1.4  107
Ampicillin 5 1b 4.2  106
Piperacillin 11 3b 3.3  106
Cephalothin 1 10 7.9  104
Cefuroxime 2 34 6.7  104
Cefotaxime 3 22 1.2  105
Ceftazidime 15 86 1.8  105
Cefepime 3 26 1.3  105
Aztreonam 2 17 1.2  105
Moxalactam NDc 26b ND
Cefoxitin ND 48b ND
a The standard deviations were below 20%.
b These values are Ki (M).
c ND, not determinable.
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The 50% inhibitory concentrations (IC50s) were determined
by measuring residual enzyme activities after preincubating the
enzyme with various concentrations of -lactamase inhibitors
for 10 min at 30°C. The IC50 of clavulanic acid was 0.55  0.05
M, as measured using ceftazidime or cefotaxime as the re-
porter substrate (data not shown), confirming that TEM-107 is
efficiently inhibited by clavulanic acid, which is in good agree-
ment with the MIC values obtained for the TEM-107-produc-
ing clinical isolate or transconjugant. We considered that prev-
alence of TEM-107-producing clinical isolates is difficult to
suspect, because the phenotype does not differ from those of
most ESBLs. Among 22 ESBL genes sequenced in a South
Korean surveillance study in 2000, there was another isolate
with TEM-107 (Enterobacter cloacae), and the most prevalent
one was TEM-52 (5 isolates) (2a).
In conclusion, the MICs of ceftazidime were much higher
than those of cefotaxime for a TEM-107-producing clinical
isolate and a transconjugant, which is in good agreement with
the higher turnover rate of TEM-107 with ceftazidime than
with cefotaxime.
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